同源康医药-B(02410)在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单

Core Viewpoint - The company, ZhiYuanKang Pharmaceutical-B (02410), has announced that its investigational first-class new drug, Tazemetostat (TY-9591), has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1: Drug Information - Tazemetostat (TY-9591) is intended for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with CNS metastases [1]